SWOG clinical trial number
CTSU/A031501
Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (ambassador) Versus Observation
Closed
Phase
Abbreviated Title
Phase III Adj Mus-Inv & Adv Uro Carc vs. Obs
Status Notes
This study is permanently closed to accrual effective 8/24/21
The FDA recently approved nivolumab, a PD-1 inhibitor (similar to pembrolizumab), as adjuvant therapy for patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection. Therefore, effective immediately, A031501 is permanently closed to new patient accrual.
Sites must review the information provided by Alliance that is available on www.ctsu.org and follow the instructions.
The FDA recently approved nivolumab, a PD-1 inhibitor (similar to pembrolizumab), as adjuvant therapy for patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection. Therefore, effective immediately, A031501 is permanently closed to new patient accrual.
Sites must review the information provided by Alliance that is available on www.ctsu.org and follow the instructions.
Activated
09/21/2017
Closed
08/24/2021
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE
Research committees
Gastrointestinal Cancer
Genitourinary Cancer
Treatment
Blinatumomab
Nivolumab
Eligibility Criteria Expand/Collapse
SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Publication Information Expand/Collapse
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase